http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103304638-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5456846495c5fa8a02f5eaae9faae290 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2013-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_54047b533c9fa02d8893472c1c3345e5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_876725e803f2fde0e8e6efb14eaa5fa5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe365099c468b1a8efa6b0dd555212d9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eacd44c3694e000da8b7ae5a39fffacb |
| publicationDate | 2014-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103304638-B |
| titleOfInvention | PD-L1 affinity peptide with anti-tumour activity and application for same |
| abstract | The invention discloses a PD-L1 affinity peptide P1 with anti-tumour activity, which is the polypeptide obtained by phage display peptide library screening, wherein the amino acid sequence thereof is FPNWSLRPMNQM, and the molecular weight thereof is1520.7. The affinity peptide P1 with anti-tumour activity and aiming at a PD-L1 target disclosed by the invention has the advantage of being screened with a high flux by utilizing a phage display peptide library screening technology for the first time; and via an in-vivo tumour-bearing experiment for Kunming mice, the affinity peptide P1 disclosed by the invention is proved to have a great anti-tumour activity, can induce the internal tumour cell apoptosis of mice, and have an extremely high killing capacity for tumour cells. Via the affinity peptide P1 disclosed by the invention, new thoughts and theoretical basis are provided for research and development on medicines based on PD-L1. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/IT-201800003470-A1 |
| priorityDate | 2013-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 36.